MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis-Reference-Cited by-同舟云学术

MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis

Published:2015-08-07 Issue:1 Volume:17 Page:
ISSN:1478-6354
Container-title:Arthritis Research & Therapy
language:en
Short-container-title:Arthritis Res Ther

Author:

Anink Janneke,Van Suijlekom-Smit Lisette W. A.,Otten Marieke H.,Prince Femke H. M.,van Rossum Marion A. J.,Dolman Koert M.,Hoppenreijs Esther P. A. H.,ten Cate Rebecca,Ursu Simona,Wedderburn Lucy R.,Horneff Gerd,Frosch Michael,Vogl Thomas,Gohar Faekah,Foell Dirk,Roth Johannes,Holzinger Dirk

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy,Rheumatology

Link

http://link.springer.com/content/pdf/10.1186/s13075-015-0723-1.pdf

Reference29 articles.

1. Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63:1638–44.

2. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al. Pediatric Rheumatology Collaborative Study G: Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58:1496–504.

3. Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis. 2009;68:635–41.

4. Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA. 2011;306:2340–7.

5. Solari N, Palmisani E, Consolaro A, Pistorio A, Viola S, Buoncompagni A, et al. Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. J Rheumatol. 2013;40:192–200.

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inflammatory biomarkers predicting long-term remission and active disease in juvenile idiopathic arthritis: a population-based study of the Nordic JIA cohort;RMD Open;2024-09

2. Diagnostic accuracy of serum calprotectin measured by CLIA and EIA in juvenile idiopathic arthritis: a proof-of-concept study;Frontiers in Pediatrics;2024-06-19

3. When to stop medication in juvenile idiopathic arthritis;Current Opinion in Rheumatology;2023-05-03

4. Circulating Calprotectin (cCLP) in autoimmune diseases;Autoimmunity Reviews;2023-05

5. Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis;Annals of the Rheumatic Diseases;2023-02-21